Phase 1, Open Label Study to Assess the Safety and Tolerability of U3-1565 in Japanese Subjects with Advanced Solid Malignant Tumors

Trial Profile

Phase 1, Open Label Study to Assess the Safety and Tolerability of U3-1565 in Japanese Subjects with Advanced Solid Malignant Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Dec 2017

At a glance

  • Drugs U3 1565 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Biomarker; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
  • Sponsors Daiichi Sankyo Company
  • Most Recent Events

    • 10 Sep 2015 Dose expansion part is ongoing at dose level of 24 mg/kg weekly dose, according to the results presented at the 2013 European Cancer Congress.
    • 10 Sep 2015 New source identified and integrated (Japan Pharmaceutical Information Center - Clinical Trials Information (JapicCTI), JapicCTI-111484).
    • 10 Sep 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top